Analysis Of Income And Expense [Abstract]

ERYTECH Pharma S.A. - Filing #880081

Concept 2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
2019-01-01 to
2019-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
EUR
EUR
EUR
Material income and expense [abstract]
Research and development expense
45 100 EUR
57 580 EUR
52 193 EUR
Finance income (cost)
2 720 EUR
4 465 EUR
1 414 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
15 595 EUR
14 970 EUR
17 164 EUR
Revenue and other operating income
4 180 EUR
3 718 EUR
5 283 EUR
Operating expense
60 695 EUR
72 550 EUR
69 357 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, before tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, before tax, exchange differences on translation of foreign operations
528,000 EUR
400,000 EUR
1 237 EUR
Income tax relating to components of other comprehensive income [abstract]
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss
EUR
EUR
EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
EUR
53 797 EUR
68,000 EUR
EUR
528,000 EUR
54 257 EUR
EUR
72 919 EUR
400,000 EUR
EUR
73 300 EUR
19,000 EUR
38,000 EUR
1 237 EUR
EUR
62 659 EUR
61 460 EUR
EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.